Compugen Reports Second Quarter 2025 Results
Provided By PR Newswire
Last update: Aug 6, 2025
HOLON, Israel, Aug. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the second quarter of 2025 and provided a corporate update.
Read more at prnewswire.com
